INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 49 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $31,558,000 | +13.4% | 35,200,000 | +2.9% | 0.01% | +11.1% |
| Q1 2021 | $27,832,000 | +257.5% | 34,200,000 | +238.6% | 0.01% | +200.0% |
| Q4 2020 | $7,786,000 | -4.1% | 10,100,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $8,120,000 | +6.8% | 10,100,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $7,601,000 | -5.9% | 10,100,000 | 0.0% | 0.00% | -25.0% |
| Q1 2020 | $8,080,000 | -66.8% | 10,100,000 | -58.1% | 0.00% | -60.0% |
| Q4 2019 | $24,301,000 | +10.4% | 24,100,000 | -5.9% | 0.01% | 0.0% |
| Q3 2019 | $22,017,000 | +38.7% | 25,601,000 | +43.8% | 0.01% | +42.9% |
| Q2 2019 | $15,871,000 | -25.1% | 17,800,000 | -16.8% | 0.01% | -30.0% |
| Q1 2019 | $21,177,000 | -3.8% | 21,400,000 | -10.5% | 0.01% | -9.1% |
| Q4 2018 | $22,021,000 | -6.1% | 23,900,000 | +3.0% | 0.01% | +37.5% |
| Q3 2018 | $23,447,000 | +13.0% | 23,200,000 | -2.1% | 0.01% | -11.1% |
| Q2 2018 | $20,751,000 | +7.0% | 23,700,000 | -2.1% | 0.01% | 0.0% |
| Q1 2018 | $19,390,000 | +7.0% | 24,200,000 | +6.1% | 0.01% | +12.5% |
| Q4 2017 | $18,125,000 | +15.6% | 22,800,000 | +12.3% | 0.01% | +14.3% |
| Q3 2017 | $15,681,000 | -20.6% | 20,300,000 | 0.0% | 0.01% | -30.0% |
| Q2 2017 | $19,741,000 | +22.5% | 20,300,000 | +17.3% | 0.01% | +25.0% |
| Q1 2017 | $16,121,000 | +52.1% | 17,300,000 | +45.5% | 0.01% | +33.3% |
| Q4 2016 | $10,596,000 | +7.7% | 11,890,000 | +35.1% | 0.01% | 0.0% |
| Q3 2016 | $9,840,000 | – | 8,800,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|